{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:05:09Z","timestamp":1794632709220,"version":"4.9.1"},"reference-count":39,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recent increases in opioid use and subsequent opioid use disorder are a major public health crisis in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This phase 1 randomized, placebo-controlled study investigated the safety, tolerability, and pharmacokinetics (PKs) of ASP8062, a \u03b3-aminobutyric acid B receptor-positive allosteric modulator, with and without administration of morphine in participants who used opioids recreationally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Participants were randomly assigned (2:1) to daily dosing with ASP8062 25\u2009mg or placebo on days 1\u201310. On day 10, all participants received morphine as a single oral dose of 45\u2009mg; assessments were performed on days 11\u201316. The primary end point was safety, evaluated as the nature, frequency, and severity of adverse events, and end-tidal CO\n                      <jats:sub>2<\/jats:sub>\n                      levels. PK end points were a secondary outcome measure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 24 participants (aged 21\u201354\u2009years) received ASP8062 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200916) or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20098). There were no deaths or serious adverse events leading to treatment discontinuation during the study. Most adverse events were mild, with numerically lower absolute number of adverse events reported with ASP8062 plus morphine versus placebo plus morphine. ASP8062 plus morphine did not increase respiratory depression, potential drug abuse- or withdrawal-related adverse events. There were no significant PK interactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this phase 1 study, we did not observe any unexpected safety signals or notable PK interactions with concomitant morphine administration. These data suggest a potentially low risk for an increase in drug abuse- or withdrawal-related adverse events or respiratory distress in participants exposed to ASP8062 and morphine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811231167852","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T03:17:12Z","timestamp":1682479032000},"page":"449-461","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA\n                    <sub>B<\/sub>\n                    receptor, and morphine in recreational opioid users"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-9019","authenticated-orcid":false,"given":"Mototsugu","family":"Ito","sequence":"first","affiliation":[{"name":"Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Walzer","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Blauwet","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spence","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakyo","family":"Heo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Exploratory Development, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Kelsh","sequence":"additional","affiliation":[{"name":"Altasciences, Clinical Kansas, Inc., Overland Park, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Blahunka","sequence":"additional","affiliation":[{"name":"Employee of Astellas, Northbrook, IL, USA, at the time of the study"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Erdman","sequence":"additional","affiliation":[{"name":"Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Nour","family":"Alsharif","sequence":"additional","affiliation":[{"name":"Development Project Management, Astellas Pharma Global Development, Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J","family":"Marek","sequence":"additional","affiliation":[{"name":"Employee of Astellas, Northbrook, IL, USA, at the time of the study"},{"name":"Gilgamesh Pharmaceuticals Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2023.02.003"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.53"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694598"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026604"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12711"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33078-2"},{"key":"e_1_3_3_8_1","unstructured":"Center for Drug Evaluation and Research (2008) Clinical Pharmacology and Biopharmaceutics Review(s). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/022195s000_022207s000_ClinPharmR.pdf (accessed 6 September 2022)."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1058-y"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(98)70230-6"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427110-00004"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300088"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14620"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.069"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.07.048"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-9-13"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05881-0"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Hedegaard H Mini\u00f1o AM Spencer MR et al. (2021) Centers for Disease Control and Prevention. Drug Overdose Deaths in the United States 1999\u20132020. Available at: https:\/\/doi.org\/10.15620\/cdc:112340 (accessed 6 September 2022).","DOI":"10.15620\/cdc:112644"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211058967."},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221149657."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1982.tb01792.x"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172750"},{"key":"e_1_3_3_26_1","unstructured":"National Institute on Drug Abuse (2020) Overdose Death Rates. Available at: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates (accessed 12 August 2022)."},{"key":"e_1_3_3_27_1","unstructured":"NCT03092726 (2022) A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03092726 (accessed 18 April 2022)."},{"key":"e_1_3_3_28_1","volume-title":"Morphine Sulfate Tablets (package insert)","author":"Package Insert: Hikma Labs Inc","year":"2012","unstructured":"Package Insert: Hikma Labs Inc (2012) Morphine Sulfate Tablets (package insert). Columbus, OH: Hikma Labs Inc."},{"key":"e_1_3_3_29_1","unstructured":"Posner K Brent D Lucas C et al. (2009) Columbia-Suicide Severity Rating Scale (C-SSRS). Available at: https:\/\/cssrs.columbia.edu\/wp-content\/uploads\/C-SSRS-Screening_AU5.1_eng-USori-2.pdf (accessed 10 April 2023)."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0292-5"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_94_20"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301049"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300734"},{"key":"e_1_3_3_34_1","unstructured":"SUBOXONE\u00ae (buprenorphine and naloxone) sublingual film (2021) SUBOXONE\u00ae (buprenorphine and naloxone) sublingual film for sublingual or buccal use. US Food & Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022410s042lbl.pdf (accessed 10 April 2023)."},{"key":"e_1_3_3_35_1","unstructured":"Substance Abuse and Mental Health Services Administration (2020) Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. Available at: https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35325\/NSDUHFFRPDFWHTMLFiles2020\/2020NSDUHFFR1PDFW102121.pdf (accessed 10 April 2023)."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202201180"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-2119-x"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3126"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.766"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05738-y"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231167852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811231167852","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231167852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:21Z","timestamp":1777507881000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811231167852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/02698811231167852"],"URL":"https:\/\/doi.org\/10.1177\/02698811231167852","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}